Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, cilt.8, sa.1, ss.42-44, 2007 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 8 Sayı: 1
- Basım Tarihi: 2007
- Doi Numarası: 10.1080/15622970600774202
- Dergi Adı: WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.42-44
- Anahtar Kelimeler: neuroleptic malignant syndrome, schizophrenia, treatment, ziprasidone
- İnönü Üniversitesi Adresli: Hayır
Özet
Neuroleptic malignant syndrome (NMS) is the rarest and most serious of the neuroleptic-induced movement disorders. We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone. Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause. The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone. This case is the earliest (second day of treatment) NMS due to ziprasidone reported in the literature.